Previous 10 | Next 10 |
HOPKINTON, Mass., July 10, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Pamela Klein,...
Gainers: OMNOVA Solutions (NYSE: OMN ) +55% . SELLAS Life Sciences Group (NASDAQ: SLS ) +46% . Karyopharm Therapeutics (NASDAQ: KPTI ) +36% . One Stop Systems (NASDAQ: OSS ) +26% . NIO (NYSE: NIO ) +15% . Corvus Pharmaceuticals (NASDAQ: CRVS ) +15% . Melinta Therapeutics (NASDA...
HOPKINTON, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has submit...
HOPKINTON, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will prese...
"Leaders bring things to conclusion, not necessarily consensus .” ― Miles Anthony Smith Today, we take a deeper look at an interesting developmental firm that just came public a few years ago. Company Overview: Spring Bank Pharmaceuticals ( SBPH ) IPO’d in 201...
HOPKINTON, Mass., June 06, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it would present p...
HOPKINTON, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscol...
ACHIEVE trial completed – inarigivir HBsAg reduction comparable to interferon but with significantly better tolerability profile Phase 2 co-administration study of inarigivir + nucleotide analogue fully enrolled – top-line results expected 2H’19 Study resu...
The following slide deck was published by Spring Bank Pharmaceuticals, Inc. in conjunction with this Read more ...
Consistent reduction in HBV DNA demonstrated with higher inarigivir doses including in high viral burden HBeAg-positive patients 26% HBsAg responder population for all inarigivir doses showed mean HBsAg change of 0.8log 10 with a range of 0.5log 10 - 1.4log 10 Inarigivir 400mg ...
News, Short Squeeze, Breakout and More Instantly...
Spring Bank Company Name:
SBPH Stock Symbol:
NASDAQ Market:
F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals To Commence Trading November 23 on Nasdaq: FSTX PR Newswire CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 CAMBRIDGE, England and CAMBRIDGE, Mass. , Nov. 20, 2020 /PRN...
CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics 1-for-4 Reverse Stock Split to be Effective November 23, 2020 PR Newswire HOPKINTON, Mass., Nov. 20, 2020 HOPKINTON, Mass. , Nov. 20, 2020 /PRNe...
HOPKINTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stock...